A disheartening story: Aprotinin in cardiac surgery: Commentary

Critical Care

Volumn 10, Issue 6, 2006, Pages

  Lien, Marcus ^a   Milbrandt, Eric B ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; TRANEXAMIC ACID;

BLEEDING; CARDIOPULMONARY BYPASS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; DOSE RESPONSE; DRUG SAFETY; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART SURGERY; HUMAN; NEPHROTOXICITY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; SHORT SURVEY; ST SEGMENT ELEVATION;

EID: 34447641987     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc5072     Document Type: Short Survey

References (10)

1. Mangano DT Tudor IC Dietzel C The risk associated with aprotinin in cardiac surgery N Engl J Med 2006 354 353-365 10.1056/NEJMoa051379 16436767
2. Cosgrove DM III Heric B Lytle BW Taylor PC Novoa R Golding LA Stewart RW McCarthy PM Loop FD Aprotinin therapy for reoperative myocardial revascularization: A placebo-controlled study Ann Thorac Surg 1992 54 1031-1036 1280411
3. D'Ambra MN Akins CW Blackstone EH Bonney SL Cohn LH Cosgrove DM Levy JH Lynch KE Maddi R Aprotinin in primary valve replacement and reconstruction: A multicenter, double-blind, placebo-controlled trial J Thorac Cardiovasc Surg 1996 112 1081-1089 10.1016/S0022-5223(96)70110-1 8873736
4. Feindt PR Walcher S Volkmer I Keller HE Straub U Huwer H Seyfert UT Petzold T Gams E Effects of high-dose aprotinin on renal function in aortocoronary bypass grafting Ann Thorac Surg 1995 60 1076-1080 10.1016/ 0003-4975(95)00525-P 7574952
5. Sundt TM III Kouchoukos NT Saffitz JE Murphy SF Wareing TH Stahl DJ Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest Ann Thorac Surg 1993 55 1418-1424 7685587
6. Umbrain V Christiaens F Camu F Intraoperative coronary thrombosis: Can aprotinin and protamine be incriminated? J Cardiothorac Vasc Anesth 1994 8 198-201 10.1016/1053-0770(94)90062-0 7515707
7. Karkouti K Beattie WS Dattilo KM McCluskey SA Ghannam M Hamdy A Wijeysundera DN Fedorko L Yau TM A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery Transfusion 2006 46 327-338 10.1111/ j.1537-2995.2006.00724.x 16533273
8. Hughes S Aprotinin safety again in spotlight as new study suggests increased cardiac events Medscape Heartwire http://www.medscape.com/ viewarticle/545400 October 2, 2006
9. Harris G FDA says Bayer failed to reveal drug risk study New York Times http://www.nytimes.com/2006/09/30/health/30fda.html September 30, 2006
10. US Food and Drug Administration FDA Public Health Advisory: Aprotinin Injection (marketed as Trasylol) http://www.fda.gov/cder/drug/advisory/ aprotinin20060929.htm September 29, 2006